NCT07230132

Efficacy and Safety of ZT006 in Overweight and Obese Participants

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Various Doses of ZT006 in Overweight and Obese Participants

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 184 (actual)
• Sponsor: Beijing QL Biopharmaceutical Co.,Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted to evaluate the efficacy and safety of ZT006 tablet in participants with overweight and obesity. In addition to dietary caloric restriction and increased physical activity, study participants will receive either ZT006 tablets or placebo tablets once every morning (placebo looks like ZT006 tablets but has no active pharmaceutical ingredients). For a fair comparison, study participants are assigned to ZT006 or placebo randomly by a computer. The treatment will last for 28 weeks. ZT006 tablets will be administered in an up-titration fashion, i.e. the dose of ZT006 will be gradually increased to reach three target doses so that the participants can tolerate its effect. Participants will have 17 clinic visits including one screening visit and one follow-up visit. Female participants who are pregnant, breast-feeding or who plan to become pregnant during the study are not allowed to participate in the study. Pregnancy will be checked by blood or urine tests during the study.

Conditions

• Overweight , Obesity

Interventions

Type	Name	Description
DRUG	ZT006	Participants will receive a daily dose of ZT006
DRUG	Placebo of ZT006	Participants will receive a daily dose of placebo of ZT006

Timeline

• Start date: 2025-12-12
• Primary completion: 2026-12-12
• Completion: 2027-03-01
• First posted: 2025-11-17
• Last updated: 2026-03-25

Locations

10 sites across 1 country: China